The frequency of AKI was statistically significantly lower in the SGLT2-Is group when compared to placebo group (2.6% vs. 3.1%, OR = 0.81; 95% CI 0.74–0.90) (Fig. 2). Here, SLC5A2 is linked to acute kidney injury.